TacticScaleWhat Sunshine Lake Pharma Does & How It Makes Money (6887.HK)
Updated October 2026 · reflects Sunshine Lake Pharma's latest reported financials
Chinese drugmaker focused on infectious diseases, chronic diseases, and cancer. It earns revenue mainly by selling its own branded and generic finished drugs, such as the flu medicine Kewei, to China's healthcare market.
How Sunshine Lake Pharma makes money
It earns revenue mainly by selling its own branded and generic finished drugs, such as the flu medicine Kewei, to China's healthcare market. It also earns money from pharmaceutical distribution and trading, and from selling active pharmaceutical ingredients and intermediates.
What Sunshine Lake Pharma does
Sunshine Lake Pharma is a Dongguan-based Chinese pharmaceutical company founded in 2001. It researches, makes, and sells drugs for infectious diseases, chronic diseases, and cancer. Its flagship is the influenza treatment Kewei, and it also sells the hepatitis C drugs Dongweien and Dongyinghe. Beyond finished drugs, the company produces chemical raw material drugs, active pharmaceutical ingredients, and intermediates. It also runs import, export, wholesale, retail, and distribution businesses. Its research pipeline covers generic drugs, biosimilars, and new biologics, so it spans both lower-cost generics and newer biological medicines.
Products & services
- Kewei (influenza treatment)
- Dongweien (hepatitis C treatment)
- Dongyinghe (hepatitis C treatment)
- Generic drugs
- Active pharmaceutical ingredients and intermediates
- Biosimilars and new biologics (in development)
What is Sunshine Lake Pharma worth?
On an owner-earnings DCF, Sunshine Lake Pharma's most-likely value is about HK$25 versus a recent price near HK$40 (60% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~HK$13) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS) · Sunflower Pharmaceutical (002737.SZ) · Shandong Lukang Pharmaceutical (600789.SS)